Please login to the form below

mongersen

This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.

The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.

Celgene pays $300m upfront for immunology start-up Delinia

other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

The UK has approved the first vaccine for COVID-19. What now?: The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle: If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....
Mapping at launch: it’s time to update the satnav: How mapping familiar basics can provide a new GPS for market access strategy that drives brand success...